(Source: Immunomedics Inc) Microsoft Word - IMMUNOMEDICS ANNOUNCES IMMU-132 IS SYNERGISTIC WITH CHEMOTHERAPEUTICS IN TNBC IMMUNOMEDICS,® INC. 300 The American Road, Morris Plains, New Jersey 07950 ¤ (973) 605-8200 ¤ Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES SACITUZUMAB GOVITECAN IS SYNERGISTIC WITH CHEMOTHERAPEUTICS THAT TARGET CELL DIVISION IN TRIPLE-NEGATIVE BREAST CANCER -- Preclinical Study Presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -- Boston, MA, November 9, 2015 --- Immunomedics, Inc. (Nasdaq: IMMU) today reported that new preclinical data for sacituzumab govitecan, the Company's lead antibody-drug conjugate (ADC) for...
↧
